[go: up one dir, main page]

MX384485B - Deteccion temprana de preeclampsia. - Google Patents

Deteccion temprana de preeclampsia.

Info

Publication number
MX384485B
MX384485B MX2016012278A MX2016012278A MX384485B MX 384485 B MX384485 B MX 384485B MX 2016012278 A MX2016012278 A MX 2016012278A MX 2016012278 A MX2016012278 A MX 2016012278A MX 384485 B MX384485 B MX 384485B
Authority
MX
Mexico
Prior art keywords
preeclampsia
subject
early detection
anxa2
level
Prior art date
Application number
MX2016012278A
Other languages
English (en)
Other versions
MX2016012278A (es
Inventor
Antonio Pellicer
Carlos Simon
Tamara Garrido
Original Assignee
Igenomix S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igenomix S L filed Critical Igenomix S L
Publication of MX2016012278A publication Critical patent/MX2016012278A/es
Publication of MX384485B publication Critical patent/MX384485B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La invención proporciona ensayos no invasivos para identificar de manera confiable mujeres que tienen o están predispuestas a desarrollar preclampsia (PE); el método comprende medir un nivel de anexina A2 (ANXA2) en una muestra de prueba obtenida de un sujeto; e identificar al sujeto que tiene preclampsia o tiene un riesgo elevado de desarrollar preclampsia cuando el nivel de ANXA2 en la muestra de prueba disminuye con relación a una muestra de control; también se proporcionan métodos para tratar a un sujeto que se ha identificado que tiene PE o está en un riesgo elevado de desarrollar preclampsia.
MX2016012278A 2014-03-21 2015-03-19 Deteccion temprana de preeclampsia. MX384485B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461968728P 2014-03-21 2014-03-21
US201461969520P 2014-03-24 2014-03-24
PCT/IB2015/001404 WO2015166353A2 (en) 2014-03-21 2015-03-19 Early detection of preeclampsia

Publications (2)

Publication Number Publication Date
MX2016012278A MX2016012278A (es) 2017-04-27
MX384485B true MX384485B (es) 2025-03-14

Family

ID=54147245

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012278A MX384485B (es) 2014-03-21 2015-03-19 Deteccion temprana de preeclampsia.

Country Status (8)

Country Link
US (1) US20170097358A1 (es)
EP (1) EP3120152A2 (es)
JP (1) JP6684263B2 (es)
CN (2) CN106662589B (es)
BR (1) BR112016021630A2 (es)
CA (1) CA2943284A1 (es)
MX (1) MX384485B (es)
WO (1) WO2015166353A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
CA2952559C (en) 2014-06-17 2023-01-24 Igenomix S.L. Stem cell therapy in endometrial pathologies
BR112020004390A2 (pt) * 2017-09-05 2020-09-08 Igenomix S.L. métodos e dispositivos para detecção de biomarcadores associados com pré-eclâmpsia
EP3781144A4 (en) * 2018-03-06 2022-01-12 The Feinstein Institutes for Medical Research METHODS TO DETECT AND TREAT ENDOMETRIOSIS
CN114990038B (zh) * 2022-05-24 2023-06-27 郑州大学 一种细菌外膜囊泡及其在制备先兆子痫治疗药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712103A (en) * 1995-02-13 1998-01-27 Regents Of The University Of California Diagnostic assay for the prediction of preeclampsia
IL127896A0 (en) * 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
US20100190192A1 (en) * 2005-09-15 2010-07-29 Victor Voroteliak Method of diagnosing pre-eclampsia
EP2147309A4 (en) * 2007-05-05 2010-08-04 Univ Western Ontario METHOD FOR DETECTING PREECLAMPSIA
EP2019318A1 (en) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
CN101290321A (zh) * 2008-04-11 2008-10-22 中国医学科学院肿瘤研究所 膜联蛋白a2的血清检测方法、检测试剂盒及其应用
US8673850B2 (en) 2008-05-30 2014-03-18 Institut De Recherches Cliniques De Montreal PCSK9 inhibitors and methods of use thereof
CN104777307B (zh) * 2008-10-31 2019-10-18 耶鲁大学 先兆子痫检测和治疗的方法和组合物
US20120107825A1 (en) * 2010-11-01 2012-05-03 Winger Edward E Methods and compositions for assessing patients with reproductive failure using immune cell-derived microrna
AU2012220872A1 (en) * 2011-02-22 2013-09-12 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers
CN104053668B (zh) * 2011-11-30 2020-09-11 新加坡科技研究局 用于生物学检测的gm1神经节苷脂与膜联蛋白v的微粒多肽比例
ES2681238T3 (es) * 2012-06-27 2018-09-12 F. Hoffmann-La Roche Ag Medios y métodos de aplicación de la relación sFlt-1/PIGF o Endoglina/PIGF para descartar la aparición de preeclampsia en un cierto periodo de tiempo
CN103436552A (zh) * 2013-09-10 2013-12-11 浙江大学 一种人源annexin A2的生产方法及其应用

Also Published As

Publication number Publication date
WO2015166353A3 (en) 2016-01-21
CN106662589B (zh) 2019-07-30
CA2943284A1 (en) 2015-11-05
EP3120152A2 (en) 2017-01-25
US20170097358A1 (en) 2017-04-06
JP2017513021A (ja) 2017-05-25
CN110927385A (zh) 2020-03-27
CN106662589A (zh) 2017-05-10
WO2015166353A2 (en) 2015-11-05
MX2016012278A (es) 2017-04-27
BR112016021630A2 (pt) 2020-02-27
JP6684263B2 (ja) 2020-04-22

Similar Documents

Publication Publication Date Title
MX2021006791A (es) Metodos y composiciones para detectar proteinas mal plegadas.
MX390772B (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
MX2016013261A (es) Metodo para la cuantificacion de huevos de parasitos en las heces.
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
BR112016027475A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático
BR112016029583A2 (pt) ?kit ou dispositivo para a detecção de câncer esofágico e método de detecção?
BR112016002668A2 (pt) métodos e kits para prognosticar o risco de ter uma doença ou evento cardiovasculares
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
WO2015131151A3 (en) Method and apparatus for determining markers of health by analysis of blood
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
MX384485B (es) Deteccion temprana de preeclampsia.
MX2016009490A (es) Ensayo novedoso para detectar periostina humana.
EP3415912A4 (en) ANALYT DETECTION PROCEDURE AND REAGENT SET TO DETECT ANALYTES
BR112016013976A2 (pt) método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método
NZ729773A (en) Biomarkers for disease progression in melanoma
EA201700208A1 (ru) Способ и устройство для обнаружения малярии
EP2937421A3 (en) Biomarker for predicting effect of an anti-C-met antibody
MX2015013993A (es) Procedimientos y series para su uso en los mismos.
EP3430406A4 (en) METHOD FOR CANCER DIAGNOSIS AND PROGNOSIS
MX2016007148A (es) Metodos de ensayo de beta-glucano.
GB201206323D0 (en) Methods and arrays for use in the same
SG10201901836PA (en) Test strip assembly
PL406989A1 (pl) Profil mikro RNA we krwi jako test wykrywania raka płuca
EP3448881A4 (en) TREATMENT OF MUTANT TUMORS OF THE HIPPO PATHWAY AND METHODS OF IDENTIFYING SUBJECTS AS CANDIDATES FOR TREATMENT